ARCHIVES

Two Phase II Studies of Ibrutinib Deliver High Response Rates

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

ASCO Annual Meeting: New Regimens Promising For Metastatic Colon Cancer

July 28, 2006

Senate Defeats Attempt To Cut NIH Funds

July 8, 1977

New Therapeutic Approaches Improve Palliative Care

June 27, 2003

TTF Increased Survival Compared To Chemotherapy

December 31, 2010

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

January 25, 2002